Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty pharmacy service in an academic health system

Journal of Managed Care Pharmacy

Volumn 19, Issue 1, 2013, Pages 49-67

  Hanson, Rebekah L ^a   Gannon, Michael J ^a   Khamo, Nehrin ^a   Sodhi, Monsheel ^a   Orr, Alexander M ^a   Stubbings, JoAnn ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; ETANERCEPT; GOLIMUMAB; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPHOID VACCINE; VARICELLA ZOSTER VACCINE;

ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; BLOOD CELL COUNT; CANCER RISK; CHECKLIST; CROHN DISEASE; DRUG CONTRAINDICATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; E-MAIL; ELECTRONIC MEDICAL RECORD; FEEDBACK SYSTEM; GRAFT REJECTION; GRANULOMATOSIS; HEALTH CARE SYSTEM; HOSPITAL PHARMACY; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MIXED CONNECTIVE TISSUE DISEASE; NEOPLASM; NURSE; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; PITYRIASIS RUBRA PILARIS; PRACTICE GUIDELINE; PREGNANCY TEST; PRESCRIPTION; PSORIASIS; PSORIATIC ARTHRITIS; PUBLICATION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SARCOIDOSIS; SPECIALTY PHARMACY SERVICE; TREATMENT RESPONSE; TUBERCULIN TEST; ULCERATIVE COLITIS; UNITED STATES; UNIVERSITY HOSPITAL; UVEITIS; VACCINATION;

EID: 84874810724     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.1.49     Document Type: Article

References (34)

1. Mullangi PK, Lokesh S, Koirala J. Role of endogenous biological response modifiers in pathogenesis of infectious diseases. Infect Dis Clin North Am. 2011;25(4):733-54.
2. Park HJ, Ranganathan P. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted? Discov Med. 2012;13(70):229-34.
3. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895-904.
4. Humira (adalimumab) [U.S. package insert and full prescribing information]. Abbott Laboratories. Last revised December 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf. Accessed January 28, 2013.
5. Enbrel (etanercept) [U.S. package insert and full prescribing information]. Amgen Wyeth, manufactured by Immunex. Last revised September 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103795s5415lbl.pdf. Accessed January 28, 2013.
6. Remicade (infliximab) [U.S. package insert and full prescribing information]. Janssen Biotech, Inc. Last revised October 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5295lbl.pdf. Accessed January 28, 2013.
7. Cimzia (certolizumab) [U.S. package insert and full prescribing information]. UCB Inc. Last revised April 2012. Available at: http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/125160s0174lbl.pdf. Accessed January 28, 2013.
8. Simponi (golimumab) [U.S. package insert and full prescribing information]. Janssen Biotech, Inc. Last revised December 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0064lbl.pdf. Accessed January 28, 2013.
9. Nasir A, Greenberg JD. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. Bull NYU Hosp Jt Dis. 2007;65(3):178-81.
10. Imperato AK, Smiles S, Abrahamson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol. 2004;16(3)199-205.
11. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 2009;15(17):2067-73.
12. Kaminska E, Patel I, Dabade TS, et al. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmark risks. J Dermatolog Treat. 2011 Jul. 14. [Epub ahead of print]
13. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18(6):1057-63.
14. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2011;43(1):1-20.
15. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of long-term data. J Rheumatol. 2011;38(8):1552-62.
16. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012;64(1):21-32.
17. Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine. 2011;78(Suppl 1):15-185.
18. Fautrel B, Constantin A, Morel J, et al. Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine. 2006;73(4):433-41.
19. Pham T, Gossec L, Fautrel B, et al. Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine. 2005;72(3):222-28.
20. Rahier JF, Moutschen M, Gompel AV, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49(10):1815-27.
21. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(4):1-4.
22. Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Intern Med J. 2010;40(2):139-49.
23. Actemra (tocilizumab) [U.S. package insert and full prescribing information]. Genentech Inc. Last updated April 2011. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/125276s0022s0023lbl.pdf. Accessed January 28, 2013.
24. Benlysta (belimumab) [U.S. package insert and full prescribing information]. GlaxoSmithKline, manufactured by Human Genome Sciences Inc. Last revised March 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2012/125370s016lbl.pdf. Accessed January 28, 2013.
25. Orencia (abatacept) [U.S. package insert and full prescribing information]. Bristol-Meyers Squibb Company. Last revised December 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/125118s0138lbl.pdf. Accessed January 28, 2013.
26. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010;49(11):2217-19.
27. Saag KG, Teng GG, Patkar NM, et al. American College of Rhematology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
28. Cush JJ, Yazici Y. Laboratory monitoring of biologic therapies. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S90-S92.
29. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 5):38-47.
30. Caporali R, Pallavicini FB, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev. 2009;8(3)274-80.
31. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679-707.
32. Stockl KM, Shin JS, Lew HC, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm. 2010;16(8):593-604.
33. Liu Y, Yang M, Chao J, Mulani PM. Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmacies. Adv Ther. 2010:27(8):523-32.
34. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDS) in patients with rheumatoid arthritis. Med Care. 2007;45(10 Suppl 2):S66-S76.